| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/31/2005 | US20050070555 Aroyl pyridinones |
| 03/31/2005 | US20050070553 Pharmaceutical composition comprising an alpha-glucosidase inhibitor and a 4-oxobutanoic acid, and the use thereof for treating diabetes |
| 03/31/2005 | US20050070552 Ion channel modulating activity I |
| 03/31/2005 | US20050070551 Novel crystalline forms of conazoles and methods of making and using the same |
| 03/31/2005 | US20050070550 Benzoimidazole compounds |
| 03/31/2005 | US20050070547 Useful in treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals; for treating conditions responsive to capsaicin receptor modulation, such as pain, itch, urinary incontinence, overactive bladder, cough, hiccup |
| 03/31/2005 | US20050070546 Tyrosine kinase inhibitors |
| 03/31/2005 | US20050070545 For treatment or prevention of metabolic and cell proliferative diseases; modifying lipid metabolism |
| 03/31/2005 | US20050070544 Such as 7-chloro-4-hydroxy-2-[3-(3-chlorophenyl)prop-2-ynyl]-1,2,5,10-tetrahydropyridazino[4,5-b]quinoline-1,10-dione; binds NMDA receptor glycine site |
| 03/31/2005 | US20050070543 Compositions of a chromene or phenyl acetic acid cyclooxygenase-2 selective inhibitor and an ACE inhibitor for the treatment of central nervous system damage |
| 03/31/2005 | US20050070542 1-(1-Ethyl-propyl)-5-(2-methoxy-4-trifluoromethoxy-phenyl)-3,6-dimethyl-1H-pyrazolo[3,4-b]pyrazine; modulators of corticotropin releasing factor receptors; for treatment of central nervous system and periphereal disorders (stress, anxiety, depression, cardiovascular disorders, and eating disorders) |
| 03/31/2005 | US20050070541 Enzyme inhibitors of cGMP-metabolizing phosphodiesterases, for TREATMENT OF CARDIOVASCULAR DIORDERS, CEREBROVASCULAR DISORDERS, UROGENITAL DISORDERS AND ERECTILE DYSFUNCTION; chemical synthesis |
| 03/31/2005 | US20050070539 Such as 1-(4-{4-[2-(cyclopropylmethyl-amino)-5-nitro-benzoyl]-piperazin-1-yl}-3-fluoro- phenyl)-ethanone for treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia, attention deficit disorders, or Alzheimer's disease |
| 03/31/2005 | US20050070538 Compounds and uses thereof in modulating amyloid beta |
| 03/31/2005 | US20050070537 Use of dihydroimidazolones for the treatment of dogs |
| 03/31/2005 | US20050070535 Antidiabetic agents; obesity; controlling appetite |
| 03/31/2005 | US20050070534 Non-peptidic NPY Y2 receptor inhibitors |
| 03/31/2005 | US20050070533 Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use |
| 03/31/2005 | US20050070532 Peroxisome proliferator activated receptors (PPARS); for inhibiting formation of adipocytes; for treatment of obesity, diabetes, hyperinsulinemia, and polycystic ovary syndrome |
| 03/31/2005 | US20050070531 Using such as 2-[2-(3-Amino-piperidin-1-yl)4-oxo-4H-quinazolin-3-ylmethyl]-benzonitrile to treat cancer and/or autoimmune disorder |
| 03/31/2005 | US20050070530 Dipeptidyl peptidase inhibitors |
| 03/31/2005 | US20050070529 Use of type 4 phosphodiesterase inhibitors in myocardial diseases |
| 03/31/2005 | US20050070526 Novel antibacterial agents |
| 03/31/2005 | US20050070525 Such as 3-[2-[4-(11,12-dihydro-6H-benzimidazo[2,1-b][3]benzazepin-6-yl)-2-(phenyl-methyl)-1-piperidinyl]ethyl]-2,10-dimethyl pyrimido[1,2- alpha ]benzimidazol-4(10H)-one |
| 03/31/2005 | US20050070524 Diagnosi of central nervous systemdisease; administering enzyme inhibitor |
| 03/31/2005 | US20050070523 For therapy of bacterial infection in a mammal |
| 03/31/2005 | US20050070517 Oxazol/thiazol-derivatives activators of the hppar-alpha receptor |
| 03/31/2005 | US20050070516 As-needed administration of an androgenic agent to enhance female desire and responsiveness |
| 03/31/2005 | US20050070514 Administering phosphodiesterase 4 inhibitor in combination with beta agonist and an anti-inflammatory steroid |
| 03/31/2005 | US20050070513 Such as ulcerative colitis and Crohn's disease |
| 03/31/2005 | US20050070512 Pharmaceutical composition and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and an estrogen agonist/antagonist |
| 03/31/2005 | US20050070511 2-methylene-19-nor-vitamin D2 compounds |
| 03/31/2005 | US20050070510 Tetracycline compound of given formula, an antifungal agent such as amphotericin B and a carrier; treating fungal infections |
| 03/31/2005 | US20050070509 Metal salts such as bis(N-cyclohexyldiazeniumdioxy)copper; treating diseases associated with mycobionts; fungicides |
| 03/31/2005 | US20050070506 Use as immunosuppressants; Sphingosine-1-phosphate (S1P1); bioassay for drugs; treating autoimmune and inflammatory diseases, e.g. respiratory diseases, infections, cancer, liver disorders, transplant rejection and graft vs host disease; use of amine-functional phosphonic acid compounds for example |
| 03/31/2005 | US20050070505 Phosphinic pseudo-peptide derivatives for the selective inhibition of the active c-terminal site of angiotensin converting enzyme (I) (ace) |
| 03/31/2005 | US20050070504 Continuous dosing schedule of one, two, or three consecutive days per month for osteoporosis, other bone disorders; patient compliance |
| 03/31/2005 | US20050070503 Antibiotics containing borinic acid complexes and methods of use |
| 03/31/2005 | US20050070502 Orally administering a starch in granulated form having a reduced surface available for enzymatic degradation, which releases reducing sugars at a controlled rate; for nocturnal hypoglycemia in diabetes patients, endurance athletes |
| 03/31/2005 | US20050070501 Water dispersible film |
| 03/31/2005 | US20050070500 Method of modulating release of saccharides and uses thereof |
| 03/31/2005 | US20050070499 Administering neuropeptide y inhibitor |
| 03/31/2005 | US20050070498 Enteral formulation |
| 03/31/2005 | US20050070496 Semi-solid formulations for the oral administration of taxoids |
| 03/31/2005 | US20050070491 Immunostimulatory nucleic acid molecules |
| 03/31/2005 | US20050070489 Adverse side effect reduction of antiviral therapy by interrupting antiviral treatment after HIV levels are suppressed, administering double stranded RNA (dsRNA) and resuming antiviral agent treatment when HIV values increase; increases the time to HIV rebound after stopping the antiviral agent therapy |
| 03/31/2005 | US20050070488 Estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy |
| 03/31/2005 | US20050070487 Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent |
| 03/31/2005 | US20050070486 Microspherules containing a pleuromutilin derivative |
| 03/31/2005 | US20050070482 Peptides substituted with a functional group that reacts with an active site residue of the targeted protease, e.g., Cyclohexylglycine BoroAla, and compounds that can hydrolyzed to produce them; improved specificity for regulating glucose metabolism |
| 03/31/2005 | US20050070481 By adding an antioxidant and/or a chelating agent in the same aqueous solution; reduced coenzyme Q10, vitamin C and ethylenediaminetetracetic acid for example |
| 03/31/2005 | US20050070480 Peptide arginals and methods for treating disseminated intravascular coagulation |
| 03/31/2005 | US20050070474 Methods of treatment and compositions therefor |
| 03/31/2005 | US20050070473 administering parathyroid hormone; antiapoptotic agents; bone disorders |
| 03/31/2005 | US20050070470 Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof |
| 03/31/2005 | US20050070468 Use of fk506 and analogues for treating allergic diseases |
| 03/31/2005 | US20050070467 Antitumor agent |
| 03/31/2005 | US20050070465 Polypeptide, the conjugate thereof with doxorubicine and a pharmaceutical composition based thereon |
| 03/31/2005 | US20050070462 Contacting with cationic polymer |
| 03/31/2005 | US20050070461 Means and methods for altering the motility of the gastrointestinal tract |
| 03/31/2005 | US20050070460 topically administering to the respiratory tract of a patient with infection, an immune response modifier compound in specific dosage to reduce infection by the agent |
| 03/31/2005 | US20050070459 treating Type I diabetes, septic shock, multiple sclerosis, inflammatory bowel disease (IBD) and Crohn's disease with BoroProline-Pinacol or other proline derivatives; dipeptidylpeptidase inhibitor |
| 03/31/2005 | US20050070015 Methods of controlling proliferation of cancer cells and cell death |
| 03/31/2005 | US20050070014 Method of expressing foreign gene in kidney |
| 03/31/2005 | US20050069989 Isoflavone-beta-D-glucan produced by agaricus blazei in the submerged liquid culture and method of producing same |
| 03/31/2005 | US20050069984 Identification of sortase gene |
| 03/31/2005 | US20050069946 Expression analysis of FKBP54 in the diagnosis and treatment of prostate cancer |
| 03/31/2005 | US20050069943 101 human secreted proteins |
| 03/31/2005 | US20050069942 Vaccine vector comprising isolated nucleic acid molecule which encodes sequence 2 linked to promoter |
| 03/31/2005 | US20050069936 Diagnostic markers of depression treatment and methods of use thereof |
| 03/31/2005 | US20050069919 Novel human secreted proteins and polynucleotides encoding the same |
| 03/31/2005 | US20050069893 Diagnostic method for glaucoma |
| 03/31/2005 | US20050069597 Method of using a compound of menthol and L-arginine as a preparation for the topical delivery of alprostadil for the treatment of female sexual dysfunction |
| 03/31/2005 | US20050069596 Compositions and methods comprising kava and anti-anxiety compounds |
| 03/31/2005 | US20050069595 Antiinflammatory agents; mixture with glucocorticoids; respiratory system disorders; antiarthritic agents |
| 03/31/2005 | US20050069593 Synergistic mixtures; nutraceuticals |
| 03/31/2005 | US20050069587 Novel drug compositions and dosage forms of topiramate |
| 03/31/2005 | US20050069586 Mixture with stabilization lubricant and excipients |
| 03/31/2005 | US20050069585 Diphenhydramine tannate liquid and semi-solid compositions and methods of use |
| 03/31/2005 | US20050069584 Diphenhydramine tannate solid dose compositions and methods of use |
| 03/31/2005 | US20050069583 Solid, digestable mixture of alginate, (bi)carbonate and polyol; gastrointestinal disorders |
| 03/31/2005 | US20050069582 Solubilized CoQ-10 |
| 03/31/2005 | US20050069580 Compositions containing both sedative and non-sedative antihistamines and sleep aids |
| 03/31/2005 | US20050069577 Synthesis and use of reagents for improved DNA lipofection and/or slow release prodrug and drug therapies |
| 03/31/2005 | US20050069563 Method for treating herpes simplex virus and fungal pimples with antifungal medication |
| 03/31/2005 | US20050069555 Vaccine adjuvants; hepatitis c virus; modulation immunology response |
| 03/31/2005 | US20050069541 Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents |
| 03/31/2005 | US20050069535 Immunotherapeutic combinations for the treatment of tumours that overexpress gangliosides |
| 03/31/2005 | US20050069522 Combination pharmaceutical agents as inhibitors of HCV replication |
| 03/31/2005 | US20050069520 Methods and compositions for treating mammalian nerve tissue injuries |
| 03/31/2005 | US20050069518 Mixture of nicotine polymer and vasodilator; promote angiogenesis; therapy for erectile dysfunction, cardiovascular disorders, strokes |
| 03/31/2005 | US20050069505 Orally administrable composition for the photoprotection of the skin |
| 03/31/2005 | US20050069499 Mixture of corticosteroid, propellant and carrier |
| 03/31/2005 | US20050069492 As neuroprotective agents in the therapy of neuronal disorders of the central and peripheral nervous systems |
| 03/31/2005 | US20050069276 Deuterated pyrazolopyrimidinones and drugs containing said compounds |
| 03/31/2005 | US20050069267 Method of making spun optical fiber with low PMD |
| 03/31/2005 | US20050067604 formed by hydrothermal treatment; x-ray diffraction |
| 03/31/2005 | DE10341317A1 Mittel zur transdermalen Applikation Means for transdermal administration |
| 03/31/2005 | DE10341179A1 Cosmetic or dermatological preparations containing synergistic combination of alpha- or beta-hydroxyacid and alkanediol, useful for combating acne and/or Propionibacterium acnes infection |
| 03/31/2005 | DE10341043A1 Neue oral zu applizierende Darreichungsform für New dosage form for oral administration for 3-[(2-{[4-Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester und dessen Salze and its salts |